Product nameAnti-VEGFA antibody
See all VEGFA primary antibodies
DescriptionRabbit polyclonal to VEGFA
SpecificityReactive with VEGF 121 as well as VEGF 165.
Tested applicationsSuitable for: Sandwich ELISA, ELISA, Neutralising, WB, IHC-Pmore details
Species reactivityReacts with: Mouse, Rat, Hamster, Human
Predicted to work with: Horse, Guinea pig, Dog, Pig
- Purchase matching WB positive control:Recombinant Human VEGFA protein
- VEGF recombinant protein
FormLyophilised:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferpH: 7.40
Concentration information loading...
PurityImmunogen affinity purified
Light chain typeunknown
sELISA pair antibody
Our Abpromise guarantee covers the use of ab9570 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Sandwich ELISA||Use at an assay dependent concentration. Can be paired for Sandwich ELISA with Rabbit polyclonal to VEGFA (Biotin) (ab83132).
To detect hVEGF by sandwich ELISA (using 100 µl/well antibody solution) a concentration of 0.5 - 2.0 µg/ml of this antibody as Detection is required. This antigen affinity purified antibody, paired with the above recommended pair, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hVEGF (ab9571).
|ELISA||Use at an assay dependent concentration. To detect hVEGF by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hVEGF.|
|Neutralising||Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of hVEGF (10.0 ng/ml), a concentration of 0.05 - 0.1 µg/ml of this antibody is required.|
|WB||Use a concentration of 0.1 - 0.2 µg/ml.|
|IHC-P||Use a concentration of 2.5 - 5.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
- Information by UniProt
- Folliculostellate cell-derived growth factor antibody
- Glioma-derived endothelial cell mitogen antibody
- MGC70609 antibody
ab9570 staining VEGF in human breast invasive ductal carcinoma section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent heat mediated antigen retrieval in sodium citrate buffer (pH 6.0). The primary antibody was used at 2.5 ug/ml and incubated with sample at 4°C overnight. A HRP-labeled polymer detection system was used with a DAB chromogen.
Lanes 2-12 : Anti-VEGFA antibody (ab9570) at 0.2 µg/ml
Lane 1 : MultiMark MultiColor Standard
Lane 2 : Recombinant Human VEGF at 0.25 µg
Lane 3 : Recombinant Human VEGF at 0.125 µg
Lane 4 : Recombinant Human VEGF at 0.0625 µg
Lane 5 : Recombinant Human VEGF at 0.03125 µg
Lane 6 : Recombinant Human VEGF at 0.015625 µg
Lane 7 : Recombinant Human VEGF at 0.0078 µg
Lane 8 : Recombinant Human VEGF at 0.0039 µg
Lane 9 : Recombinant Human VEGF at 0.00195 µg
Lane 10 : Recombinant Human VEGF at 0.000975 µg
Lane 11 : Recombinant Human VEGF at 0.0004875 µg
Lane 12 : Recombinant Human VEGF at 0.00024 µg
Performed under non-reducing conditions.
Observed band size: 38.2 kDa why is the actual band size different from the predicted?
Detected human VEGF in a sandwich ELISA within the range 16-1000 pg/ml
- 0.5 µg/ml of capture antibody (ab9570)
- 0.25 µg/ml of detection antibody (ab83132)
Lanes 2-12 : Anti-VEGFA antibody (ab9570)
Lane 1 : Molecular weight ladder
Lane 2 : Recombinant human VEGFA at 0.25 µg
Lane 3 : Recombinant human VEGFA at 0.125 µg
Lane 4 : Recombinant human VEGFA at 0.0625 µg
Lane 5 : Recombinant human VEGFA at 0.03125 µg
Lane 6 : Recombinant human VEGFA at 0.015625 µg
Lane 7 : Recombinant human VEGFA at 0.0078 µg
Lane 8 : Recombinant human VEGFA at 0.0039 µg
Lane 9 : Recombinant human VEGFA at 0.00195 µg
Lane 10 : Recombinant human VEGFA at 0.000975 µg
Lane 11 : Recombinant human VEGFA at 0.0004875 µg
Lane 12 : Recombinant human VEGFA at 0.00024 µg
Performed under reducing conditions.
This product has been referenced in:
- Efeoglu FB et al. Effects of omentin on flap viability: an experimental research on rats. J Plast Surg Hand Surg N/A:1-9 (2019). Read more (PubMed: 31244355) »
- Li Y et al. Artesunate, an Anti-Malaria Agent, Attenuates Experimental Osteoarthritis by Inhibiting Bone Resorption and CD31hiEmcnhi Vessel Formation in Subchondral Bone. Front Pharmacol 10:685 (2019). Read more (PubMed: 31258481) »